TyG and TyG/HDL-c Signal Diabetes Risk in Nonalcoholic Fatty Liver Disease: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-30 03:30 GMT   |   Update On 2025-06-30 06:02 GMT

New evidence has revealed that both triglyceride-glucose index (TyG) and (TyG/HDL-c) were linked to increased risk of diabetes in patients with NAFLD (OR 1.96 and 1.90, resp). Non-linear associations were observed, with the TyG threshold at 2.39 and the TyG/HDL-c at 2.20. Both markers showed stronger risk association in females. Their combined use offered superior diagnostic accuracy than either index alone (AUC 0.70)

This study seeks to investigate the association between the triglyceride-glucose index (TyG), triglyceride glucose index to high-density lipoprotein cholesterol ratio (TyG/HDL-c), and the risk of diabetes in individuals with nonalcoholic fatty liver disease (NAFLD).

This retrospective study encompassed 457 NAFLD patients from The Central Hospital of Shaoyang, monitored over a three-year period. Missing data were addressed using multiple imputation, and the Synthetic Minority Over-sampling Technique (SMOTE) was employed to balance the dataset.

Multicollinearity analysis was conducted to evaluate the collinearity among variables, while principal component analysis was utilized to examine the distribution of variables in both the original and balanced datasets. A multivariate logistic regression model was used to assess the association between TyG, TyG/HDL-c, and the risk of diabetes in NAFLD patients, adjusting for various covariates. Subgroup analysis was performed to identify differences across diverse populations, and restricted cubic splines (RCS) were used to explore potential non-linear relationships. The receiver operating characteristic (ROC) curve examined the diagnostic value of individual and combined indicators in assessing the risk of diabetes in NAFLD patients.

Results: Upon adjustment for all covariates, TyG was found to significantly elevate the risk of diabetes among patients with NAFLD (OR = 1.96, 95% CI: 1.67-2.30, P < 0.001), with a notable non-linear relationship observed (threshold: 2.39, P-nonlinear = 0.002). Similarly, TyG/HDL-c significantly increased diabetes risk (OR = 1.90, 95% CI: 1.60-2.26, P < 0.001), also demonstrating a distinct non-linear association (threshold: 2.20, P-nonlinear < 0.001). Subgroup analyses revealed significant interactions between TyG and TyG/HDL-c across different gender subgroups (P for interaction < 0.05). The ROC curve analysis indicated that the combined use of TyG and TyG/HDL-c provided superior diagnostic performance for assessing diabetes risk in NAFLD patients (Area Under the Curve [AUC]: 0.703, 95% CI: 0.665-0.740), compared to the use of TyG (AUC: 0.694, 95% CI: 0.656-0.732) or TyG/HDL-c (AUC: 0.693, 95% CI: 0.655-0.731) independently.

Both TyG and TyG/HDL-c are significantly associated with an increased risk of diabetes in NAFLD patients, exhibiting non-linear relationships. Furthermore, these associations vary significantly across gender subgroups, their combined use enhances risk assessment, supporting their clinical utility in evaluating diabetes risk.

Reference:

Sun Tao , Liu Jun. Study on the correlation between triglyceride glucose index, triglyceride glucose index to high-density lipoprotein cholesterol ratio, and the risk of diabetes in nonalcoholic fatty liver disease. Frontiers in Endocrinology. Volume 16 - 2025. 2025. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1594548. DOI=10.3389/fendo.2025.1594548

Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News